US Stock Futures Slip Ahead Of Home Price, Consumer Confidence Data

Loading...
Loading...
Pre-open movers
US stock futures traded lower in early pre-market trade. The S&P/Case-Shiller home price index for October will be released at 9:00 a.m. ET, while the Conference Board's consumer confidence Index for December will be released at 10:00 a.m. ET. Futures for the Dow Jones Industrial Average dropped 26 points to 17,956.00, while the Standard & Poor's 500 index futures fell 5.20 points to 2,080.60. Futures for the Nasdaq 100 index slipped 6.25 points to 4,304.75.
A Peek Into Global Markets
European markets were lower today, with the Spanish Ibex Index falling 0.81%, STOXX Europe 600 Index dropping 0.51%. German DAX 30 index slipped 0.68%, French CAC 40 Index slipped 0.86% and London's FTSE 100 Index fell 0.82%. In Asian markets, Japan's Nikkei Stock Average declined 1.57%, Hong Kong's Hang Seng Index tumbled 1.14%, China's Shanghai Composite Index fell 0.07% and India's Sensex jumped 0.57%.
Broker Recommendation
Analysts at Rafferty Capital downgraded
BB&T CorporationBBT
from Buy to Hold. The price target for BB&T has been lowered from $45 to $41. BB&T's shares closed at $39.37 yesterday.
Breaking news
  • New York REIT, Inc. NYRT announced today that its Board of Directors has appointed Michael Happel, the Company's President, to the role of Chief Executive Officer, effective immediately. To read the full news, click here.
  • Acacia Research Corporation ACTG announced today that its Body Science LLC subsidiary has entered into a settlement agreement with A&D Engineering, Inc. regarding wireless medical diagnostic and monitoring systems. To read the full news, click here.
  • OncoGenex Pharmaceuticals, Inc. OGXI today announced that it has executed an initial agreement with Teva Pharmaceutical Industries Ltd. TEVA to regain rights to custirsen, an investigational compound currently being evaluated in Phase 3 clinical development as a treatment for prostate and lung cancers. To read the full news, click here.
  • Alexion Pharmaceuticals, Inc. ALXN announced today completion of the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for asfotase alfa, an investigational, first-in-class enzyme replacement therapy for the treatment of hypophosphatasia (HPP). To read the full news, click here.
Loading...
Loading...
Market News and Data brought to you by Benzinga APIs
Posted In: NewsEurozoneFuturesGlobalPre-Market OutlookMarketsRafferty CapitalUS Stock Futures
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...